Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

By D. Soulières, N. Senzer, E. Vokes, M. Hidalgo, S. Agarwala, L. Siu. Journal of Clinical Oncology, 2004

816 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023, result): “Most adverse events associated with erlotinib plus gemcitabine treatment in this study were mild-to-moderate, and consistent with previous experience with both agents.(2,22,23) Rash was more frequent with erlotinib plus gemcitabine than placebo plus gemcitabine and we did observe an association betw”
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma (2011, background): “Erlotinib/ Gefitinib/ Lapatinib Anti-EGFR receptor kinase Erlotinib: Phase II study in refractory/metastatic HNSCC Gefatinib: PhaseIII vs methotraxate in recurrent HNSCC [205-207]”
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. (2005, background): “In clinical studies, the acneiform eruption caused by EGFR inhibitors is usually classified according to the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC v2.0) [2, 3, 5, 12, 14, 15 , 18] (Table 2) or the more recent National Cancer Institute Common Terminology Criteria fo”